CYP2C19*2 en *3
Conditions
Interventions
None listed
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: - adult patients (age > 18 years) - obtained written informed consent - patients with the ability to perform a buccal swab at home - patients who were treated for an infrarenal AAA with EVAR between January 2016 and July 2019, including those that were additionally treated with an iliac branched device and/or coiling of the internal iliac artery - patients who are on continues treatment with clopidogrel as single thrombocyte aggregation inhibitor since EVAR
Exclusion criteria
Exclusion criteria: - patients with a known CYP2C19*2 and *3 status - patients who are treated with other antithrombotic medications (aspirin, ticagrelor, prasugrel, coumarins, Non-vitamin K Oral Anti-Coagulants (NOACs), in combination with clopidogrel - Patient treated for a juxtarenal AAA with Fenestrated-EVAR, Chimney-EVAR or open surgical repair - Patients that have used clopidogral only temporary after EVAR
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints will include (a)symptomatic in-stent or mural thrombus formation, endograft patency rates, aneurysm-related reinterventions, all major and clinically relevant minor bleeding complications and renal function. | — |
Primary
| Measure | Time frame |
|---|---|
| The primary outcome will be the incidence of Major Adverse Cardiac Events (MACE) and Major Adverse Limb events (MALE). | — |
Countries
Netherlands
Outcome results
None listed